Mike Mussallem

“In the second quarter, total company sales reflected year-over-year and sequential growth across all four of our product groups on a constant currency basis, despite several challenging factors.”

“Let me begin by saying I remain very proud of our team's steadfast dedication to our patient-focused strategy. Throughout the first quarter, our supply chain delivered, and our field team continued to support the skilled clinicians and patients who count on Edwards.”

“Although hospitals continued to be impacted by COVID, it was a year of significant milestones and investments for Edwards, and our teams were relentless. In TAVR, we made important strides in executing our long-term strategy.”

“Let me begin by expressing appreciation for our global teams who have been highly engaged throughout the pandemic. We're also pleased that our supply chain remained resilient during these challenging times to meet the needs of the patients we serve.”

“We were encouraged by the clear signs of recovery during the second quarter. Vaccine adoption in key regions has contributed to an increasing number of patients seeking and, most importantly, receiving treatment.”